Noninvasive contrast-enhanced US quantitative assessment of tumor microcirculation in a murine model: Effect of discontinuing anti-VEGF therapy

Radiology

Volumn 254, Issue 2, 2010, Pages 420-429

  Guibal, Aymeric ^a,b   Taillade, Laurent ^a,c,d   Mulé, Sébastien ^b   Comperat, Eva ^a   Badachi, Yasmina ^a   Golmard, Jean Louis ^c   Le Guillou Buffello, Delphine ^c,d   Rixe, Olivier ^a   Bridal, S Lori ^c   Lucidarme, Olivier ^a,b  

^a ASSISTANCE PUBLIQUE HÔPITAUX DE PARIS   (France)

^b INSERM   (France)

^c SORBONNE UNIVERSITÉ   (France)

^d CNRS   (France)

Author keywords

[No Author keywords available]

Indexed keywords

BEVACIZUMAB; PLACEBO; ANGIOGENESIS INHIBITOR; CONTRAST AGENT BR1; CONTRAST MEDIUM; MONOCLONAL ANTIBODY; PHOSPHOLIPID; SULFUR HEXAFLUORIDE; VASCULOTROPIN A;

ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; CONTROLLED STUDY; ECHOGRAPHY; FEMALE; FOLLOW UP; KIDNEY CORTEX; KIDNEY PERFUSION; KIDNEY TUMOR; MICROBUBBLE; MOUSE; NONHUMAN; PRIORITY JOURNAL; TREATMENT DURATION; TUMOR BLOOD FLOW; ANALYSIS OF VARIANCE; ANIMAL; DRUG ANTAGONISM; EXPERIMENTAL NEOPLASM; HUMAN; MICROCIRCULATION; NEOVASCULARIZATION (PATHOLOGY); NUDE MOUSE; TUMOR CELL LINE;

ANALYSIS OF VARIANCE; ANGIOGENESIS INHIBITORS; ANIMALS; ANTIBODIES, MONOCLONAL; CELL LINE, TUMOR; CONTRAST MEDIA; FEMALE; HUMANS; MICE; MICE, NUDE; MICROCIRCULATION; NEOPLASMS, EXPERIMENTAL; NEOVASCULARIZATION, PATHOLOGIC; PHOSPHOLIPIDS; SULFUR HEXAFLUORIDE; VASCULAR ENDOTHELIAL GROWTH FACTOR A;

EID: 77449158077     PISSN: 00338419     EISSN: 15271315     Source Type: Journal    
DOI: 10.1148/radiol.09090728     Document Type: Article

References (35)

1. Carmeliet P, Jain RK. Angiogenesis in cancer and other diseases. Nature 2000;407:249-257.
2. Ferrara N. VEGF and the quest for tumour angiogenesis factors. Nat Rev Cancer 2002;2:795-803.
3. Hurwitz H, Fehrenbacher L, Novotny W, et al. Bevacizumab plus irinotecan, fluorouracil, and leucovorin for metastatic colorectal cancer. N Engl J Med 2004;350:2335 -2342.
4. Escudier B, Eisen T, Stadler WM, et al. Sorafenib in advanced clear-cell renal-cell carcinoma. N Engl J Med 2007;356:125-134.
5. Motzer RJ, Hutson TE, Tomczak P, et al. Sunitinib versus interferon alfa in metastatic renal-cell carcinoma. N Engl J Med 2007;356:115-124.
6. Forsberg F, Ro RJ, Potoczek M, et al. Assessment of angiogenesis: implications for ultrasound imaging. Ultrasonics 2004;42:325-330.
7. McCarville MB, Streck CJ, Dickson PV, Li CS, Nathwani AC, Davidoff AM. Angiogenesis inhibitors in a murine neuroblastoma model: quantitative assessment of intratumoral blood flow with contrast-enhanced gray-scale US. Radiology 2006;240:73-81.
8. Lavisse S, Lejeune P, Rouffiac V, et al. Early quantitative evaluation of a tumor vasculature disruptive agent AVE8062 using dynamic contrast-enhanced ultrasonography. Invest Radiol 2008;43:100-111.
9. Emoto M, Tachibana K, Iwasaki H, Kawarabayashi T. Antitumor effect of TNP-470, an angiogenesis inhibitor, combined with ultrasound irradiation for human uterine sarcoma xenografts evaluated using contrast color Doppler ultrasound. Cancer Sci 2007;98:929-935.
10. Escudier B, Lassau N, Angevin E, et al. Phase I trial of sorafenib in combination with IFN alpha-2a in patients with unresectable and/or metastatic renal cell carcinoma or malignant melanoma. Clin Cancer Res 2007;13:1801-1809.
11. Pollard RE, Broumas AR, Wisner ER, Vekich SV, Ferrara KW. Quantitative contrast enhanced ultrasound and CT assessment of tumor response to antiangiogenic therapy in rats. Ultrasound Med Biol 2007;33:235-245.
12. Scappaticci FA, Fehrenbacher L, Cartwright T, et al. Surgical wound healing complications in metastatic colorectal cancer patients treated with bevacizumab. J Surg Oncol 2005;91:173-180.
13. Jouannot E, Duong-Van-Huyen JP, Bourahla K, Laugier P, Lelievre-Pegorier M, Bridal L. High-frequency ultrasound detection and follow-up of Wilms' tumor in the mouse. Ultrasound Med Biol 2006;32:183-190.
14. Greis C. Technology overview: SonoVue (Bracco, Milan). Eur Radiol 2004;14(suppl 8):P11-P15.
15. Phillips P, Gardner E. Contrast-agent detection and quantification. Eur Radiol 2004;14(suppl 8):P4-P10.
16. Schneider M, Arditi M, Barrau MB, et al. BR1: a new ultrasonographic contrast agent based on sulfur hexafluoride-filled microbubbles. Invest Radiol 1995;30:451-457.
17. Janssen BJ, Smits JF. Autonomic control of blood pressure in mice: basic physiology and effects of genetic modification. Am J Physiol Regul Integr Comp Physiol 2002;282:R1545-R1564.
18. Arditi M, Frinking PJ, Zhou X, Rognin NG. A new formalism for the quantification of tissue perfusion by the destruction-replenishment method in contrast ultrasound imaging. IEEE Trans Ultrason Ferroelectr Freq Control 2006;53:1118-1129.
19. Wei K, Jayaweera AR, Firoozan S, Linka A, Skyba DM, Kaul S. Quantification of myocardial blood flow with ultrasound-induced destruction of microbubbles administered as a constant venous infusion. Circulation 1998;97:473-483.
20. Balvay D, Frouin F, Calmon G, et al. New criteria for assessing fit quality in dynamic contrast-enhanced T1-weighted MRI for perfusion and permeability imaging. Magn Reson Med 2005;54:868-877.
21. Weidner N. Intratumor microvessel density as a prognostic factor in cancer. Am J Pathol 1995;147:9-19.
22. Weidner N, Carroll PR, Flax J, Blumenfeld W, Folkman J. Tumor angiogenesis correlates with metastasis in invasive prostate carcinoma. Am J Pathol 1993;143:401-409.
23. Weidner N, Folkman J, Pozza F, et al. Tumor angiogenesis: a new significant and independent prognostic indicator in early-stage breast carcinoma. J Natl Cancer Inst 1992;84:1875-1887.
24. Weidner N, Semple JP, Welch WR, Folkman J. Tumor angiogenesis and metastasis: correlation in invasive breast carcinoma. N Engl J Med 1991;324:1-8.
25. Huang J, Frischer JS, Serur A, et al. Regression of established tumors and metastases by potent vascular endothelial growth factor blockade. Proc Natl Acad Sci U S A 2003;100:7785-7790.
26. Huang J, Moore J, Soffer S, et al. Highly specific antiangiogenic therapy is effective in suppressing growth of experimental Wilms tumors. J Pediatr Surg 2001;36:357-361.
27. Soffer SZ, Kim E, Moore JT, et al. Novel use of an established agent: Topotecan is anti-angiogenic in experimental Wilms tumor. J Pediatr Surg 2001;36:1781-1784.
28. Gerber HP, Ferrara N. Pharmacology and pharmacodynamics of bevacizumab as monotherapy or in combination with cytotoxic therapy in preclinical studies. Cancer Res 2005;65:671-680.
29. Presta LG, Chen H, O'Connor SJ, et al. Humanization of an anti-vascular endothelial growth factor monoclonal antibody for the therapy of solid tumors and other disorders. Cancer Res 1997;57:4593-4599.
30. Rowe DH, Huang J, Kayton ML, et al. Anti-VEGF antibody suppresses primary tumor growth and metastasis in an experimental model of Wilms' tumor. J Pediatr Surg 2000;35:30-32, discussion 32-33.
31. Gerber HP, Kowalski J, Sherman D, Eberhard DA, Ferrara N. Complete inhibition of rhabdomyosarcoma xenograft growth and neovascularization requires blockade of both tumor and host vascular endothelial growth factor. Cancer Res 2000;60:6253-6258.
32. Lin YS, Nguyen C, Mendoza JL, et al. Preclinical pharmacokinetics, interspecies scaling, and tissue distribution of a humanized monoclonal antibody against vascular endothelial growth factor. J Pharmacol Exp Ther 1999;288:371-378.
33. Jain RK. Normalizing tumor vasculature with anti-angiogenic therapy: a new paradigm for combination therapy. Nat Med 2001;7:987-989.
34. Jain RK. Normalization of tumor vasculature: an emerging concept in antiangiogenic therapy. Science 2005;307:58-62.
35. Gerber HP, Wu X, Yu L, et al. Mice expressing a humanized form of VEGF-A may provide insights into the safety and efficacy of anti-VEGF antibodies. Proc Natl Acad Sci U S A 2007;104:3478-3483.